In this article, we will explore BMS-906024 from different perspectives and in various contexts. BMS-906024 is a topic that has sparked interest and debate over time, and its relevance continues to be evident today. Through this article, we will delve into the multiple aspects that BMS-906024 encompasses, addressing its implications, its history, its impact on today's society, as well as the possible perspectives offered by experts and scholars on the subject. Likewise, we will examine different opinions and points of view in relation to BMS-906024, with the purpose of providing the reader with a complete and enriching vision on this topic.
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
PubChem SID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H26F6N4O3 |
Molar mass | 556.509 g·mol−1 |
3D model (JSmol) | |
| |
|
BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia. The drug works as a pan-Notch inhibitor. The structure is one of a set patented in 2012, and is being studied in clinical trials.